Cipla Limited (CIPLA) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹1,403.8 (-0.14% day change)
Key ratios
- P/E ratio
- 29.23
- P/B ratio
- 2.87
- ROE (%)
- 11.27
- ROCE (%)
- 13.29
- Debt/Equity
- 0.02
- Dividend yield (%)
- 1.31
- Market cap (₹ Cr)
- 113,408.93
Forensic checks
Piotroski F-Score: 3/9 · Altman Z-Score: 13.34 · Beneish M-Score: -2.3
InvestSights quality score
68.3/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- R&D expenditure as a percentage of revenue: guided 5–6%, delivered 5.6% (FY25) — met guidance
- R&D expenditure as a percentage of revenue: guided 7%, delivered 7% (FY26) — met guidance
Latest earnings call (Q2 FY27)
AI summary: The central signal was management’s continued confidence in reaching a $1 billion annualised North America revenue run rate by FY27-end despite Q2 revenue of $172 million, delayed Advair commercialisation and the absence of Lanreotide. The bridge rests primarily on manufacturing execution: Ventolin’s constraint is supply rather than demand, and management expects a…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.